Minireviews
Copyright ©The Author(s) 2016.
World J Gastrointest Oncol. Sep 15, 2016; 8(9): 682-687
Published online Sep 15, 2016. doi: 10.4251/wjgo.v8.i9.682
Table 1 Randomized second line studies
Ref.YearStudyRegimensPatientsOS (mo)
Pelzer et al[19]2011CONKO-01OFF vs BSC234.8 vs 2.3
Oettle et al[6]2014CONKO-003OFF vs 5-FU765.9 vs 3.3
Wang-Gillam et al[45]2015NAPOLI 1Nal-iri + 5-FU + LLV vs Nal-iri vs 5-FU + LLV4176.1 vs 4.9 vs 4.2
Ulrich-Pur et al[30]2003Raltitrexed + irinotecan vs raltitrexed386.5 vs 4.3
Table 2 Most significant not randomized second line studies
Ref.Year studyRegimensPatientsOS (mo)
Reni et al[22]2006Oxaliplatin + Raltitrexed415.2
Demols et al[23]2006Oxaliplatin + Gemcitabine336
Saif et al[25]2010Docetaxel174
Yi et al[31]2009Irinotecan336.6
Zaniboni et al[32]2012Folfiri505
Bertocchi et al[40]2015Abraxane + gemcitabine235